• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The economic burden of metastatic breast cancer in Spain.转移性乳腺癌在西班牙的经济负担。
Eur J Hosp Pharm. 2020 Jan;27(1):19-24. doi: 10.1136/ejhpharm-2017-001453. Epub 2018 Jul 30.
2
HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.HR+/HER2- 转移性乳腺癌：来自大型意大利真实世界数据库的流行病学、处方模式、医疗资源利用和成本。
Clin Drug Investig. 2019 Oct;39(10):945-951. doi: 10.1007/s40261-019-00822-4.
3
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.美国 HR+/HER2-转移性乳腺癌私人保险患者的治疗模式、不良反应、直接和间接经济负担。
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):699-710. doi: 10.1080/14737167.2020.1804871. Epub 2020 Sep 14.
4
HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.人表皮生长因子受体 2 阳性转移性乳腺癌：靶向治疗时代医疗成本的回顾性队列研究。
Adv Ther. 2020 Apr;37(4):1632-1645. doi: 10.1007/s12325-020-01283-4. Epub 2020 Mar 14.
5
Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.对接受依维莫司治疗或化疗的HR+/HER2-转移性乳腺癌老年女性的医疗成本和医疗资源利用的真实世界分析。
Adv Ther. 2016 Jun;33(6):983-97. doi: 10.1007/s12325-016-0328-3. Epub 2016 May 23.
6
Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.与 III 期至 IV 期三阴性乳腺癌相关的临床和经济负担：美国老年女性 SEER-Medicare 历史队列研究。
Cancer. 2018 May 15;124(10):2104-2114. doi: 10.1002/cncr.31299. Epub 2018 Mar 5.
7
Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.帕博西尼药物浪费的剂量模式和经济负担在 HR+/HER2-转移性乳腺癌。
Adv Ther. 2018 Jun;35(6):768-778. doi: 10.1007/s12325-018-0701-5. Epub 2018 Jun 4.
8
Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review.研究 HER2 阴性和三阴性转移性乳腺癌治疗、生活质量和成本的结果：系统文献回顾。
J Comp Eff Res. 2018 Jan;7(1):67-83. doi: 10.2217/cer-2017-0027. Epub 2018 Jan 5.
9
Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.遗传性 BRCA1/2 突变的转移性乳腺癌患者的临床结局、治疗模式和卫生资源利用：一项真实世界回顾性研究。
Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
10
Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.在美国一个大型医疗计划数据库中，HR+/HER2-转移性乳腺癌女性患者一线治疗的临床和经济结局。
Curr Med Res Opin. 2016 Aug;32(8):1417-23. doi: 10.1080/03007995.2016.1178108. Epub 2016 May 12.

引用本文的文献

1
The economic burden of breast cancer in western Iran: a cross-sectional cost-of-illness study.伊朗西部乳腺癌的经济负担：一项横断面疾病成本研究。
J Health Popul Nutr. 2025 Jan 22;44(1):16. doi: 10.1186/s41043-025-00738-0.
2
Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis.意大利乳腺癌的疾病负担：一项真实世界数据分析。
Pharmacoecon Open. 2025 Mar;9(2):283-290. doi: 10.1007/s41669-024-00543-1. Epub 2024 Nov 23.
3
A systematic literature review on direct and indirect costs of triple-negative breast cancer.一项关于三阴性乳腺癌直接和间接成本的系统文献综述。
Cost Eff Resour Alloc. 2023 Nov 30;21(1):92. doi: 10.1186/s12962-023-00503-2.
4
Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.临床实践中的药物使用与成人实体瘤患者癌症治疗相关成本：一项回顾性 10 年队列研究。
Curr Oncol. 2023 Aug 30;30(9):7984-8004. doi: 10.3390/curroncol30090580.
5
Clinical and cost outcomes of a polyethylene glycol (PEG)-coated patch versus drainage after axillary lymph node dissection in breast cancer: results from a multicentre randomized clinical trial.乳腺癌腋窝淋巴结清扫术后应用聚乙二醇（PEG）涂层贴剂与引流的临床和成本结局：来自一项多中心随机临床试验的结果。
Br J Surg. 2023 Aug 11;110(9):1180-1188. doi: 10.1093/bjs/znad150.
6
A systemmatic literature review on indirect costs of women with breast cancer.一项关于乳腺癌女性间接成本的系统文献综述。
Cost Eff Resour Alloc. 2022 Dec 12;20(1):68. doi: 10.1186/s12962-022-00408-6.
7
Cancer Survivors' Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q).澳大利亚昆士兰州癌症幸存者的长期健康服务费用：基于人群水平数据链接研究（Cos-Q）的结果。
Int J Environ Res Public Health. 2022 Aug 2;19(15):9473. doi: 10.3390/ijerph19159473.
8
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer - a Danish register-based study from 2005 to 2016.2005 年至 2016 年丹麦登记研究：HER2 阳性和转移性及复发性 HER2 阳性乳腺癌的疾病经济负担
BMC Health Serv Res. 2022 Jun 4;22(1):745. doi: 10.1186/s12913-022-08143-7.
9
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.三阴性乳腺癌的经济和人文负担：一项系统文献综述
Pharmacoeconomics. 2022 May;40(5):519-558. doi: 10.1007/s40273-021-01121-7. Epub 2022 Feb 3.
10
Hospitalization and ambulatory costs related to breast cancer due to physical inactivity in the Brazilian state capitals.巴西各州府因缺乏身体活动导致的乳腺癌住院和门诊费用。
PLoS One. 2022 Jan 19;17(1):e0261019. doi: 10.1371/journal.pone.0261019. eCollection 2022.

本文引用的文献

1
Defining the optimal sequence for the systemic treatment of metastatic breast cancer.确定转移性乳腺癌全身治疗的最佳顺序。
Clin Transl Oncol. 2017 Feb;19(2):149-161. doi: 10.1007/s12094-016-1520-2. Epub 2016 Jun 17.
2
SEOM clinical guidelines in metastatic breast cancer 2015.2015年SEOM转移性乳腺癌临床指南
Clin Transl Oncol. 2015 Dec;17(12):946-55. doi: 10.1007/s12094-015-1476-7. Epub 2015 Dec 18.
3
Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey.在英国、德国、法国、西班牙和意大利（欧盟-5 国家），转移性乳腺癌患者按激素受体和 HER2 状态的治疗模式：一项医生调查的结果。
J Comp Eff Res. 2012 Sep;1(5):453-63. doi: 10.2217/cer.12.43.
4
Economic burden of cancer across the European Union: a population-based cost analysis.欧盟癌症的经济负担：基于人群的成本分析。
Lancet Oncol. 2013 Nov;14(12):1165-74. doi: 10.1016/S1470-2045(13)70442-X. Epub 2013 Oct 14.
5
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.转移性乳腺癌亚型的预后：激素受体/HER2 阳性亚型与最佳结局相关。
Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.
6
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.纳米白蛋白结合紫杉醇与紫杉醇单药治疗西班牙预处理转移性乳腺癌的成本效用分析。
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):381-91. doi: 10.1586/erp.13.18. Epub 2013 Mar 28.
7
Factors affecting 5- and 10-year survival of women with breast cancer: an analysis based on a public general hospital in Barcelona.影响乳腺癌女性 5 年和 10 年生存率的因素：基于巴塞罗那一家公立综合医院的分析。
Cancer Epidemiol. 2012 Dec;36(6):554-9. doi: 10.1016/j.canep.2012.07.003. Epub 2012 Jul 31.
8
Incidence-based cost-of-illness model for metastatic breast cancer in the United States.美国转移性乳腺癌基于发病率的疾病成本模型。
Int J Technol Assess Health Care. 2012 Jan;28(1):12-21. doi: 10.1017/S026646231100064X.
9
Cost-of-illness studies: a guide to critical evaluation.疾病负担研究：批判性评估指南。
Pharmacoeconomics. 2011 Aug;29(8):653-71. doi: 10.2165/11588380-000000000-00000.
10
The economic burden of metastatic breast cancer: a systematic review of literature from developed countries.转移性乳腺癌的经济负担：来自发达国家的文献系统评价。
Cancer Treat Rev. 2011 Oct;37(6):405-15. doi: 10.1016/j.ctrv.2010.12.008. Epub 2011 Apr 8.

转移性乳腺癌在西班牙的经济负担。

The economic burden of metastatic breast cancer in Spain.

机构信息

Hospital Clinico Universitario de Valencia, Valencia, Spain.

Madrid & Vall d'Hebron Institute of Oncology (VHIO), University Hospital, Barcelona, Spain.

出版信息

Eur J Hosp Pharm. 2020 Jan;27(1):19-24. doi: 10.1136/ejhpharm-2017-001453. Epub 2018 Jul 30.

DOI:10.1136/ejhpharm-2017-001453
PMID:32064084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6992969/
Abstract

OBJECTIVES

The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.

METHODS

An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.

RESULTS

The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2-/HR+, 520 HER2+/HR+, 324 HER2+/HR-, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2-/HR+, 2.82 years for HER2+/HR- and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR-and €94,572 for triple negative patients over 5 years.

CONCLUSIONS

The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2-/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.

摘要

目的

本研究旨在估计西班牙 5 年内转移性乳腺癌（mBC）的负担。

方法

采用基于发病率的疾病成本模型，对 mBC 患者进行了随访，从转移性疾病诊断开始，随访 5 年或死亡。通过在西班牙的 10 位临床专家进行的医生调查收集资源使用数据。该模型根据人表皮生长因子受体 2（HER2）和激素受体（HR）状态区分患者，并按月周期随访患者队列。

结果

估计有 2923 例 mBC 新发病例，其中 1575 例为 HER2-/HR+，520 例为 HER2+/HR+，324 例为 HER2+/HR-，503 例为三阴性。在 5 年期间，估计平均生存时间为 2.51 年，HER2+/HR+的生存时间较长，为 3.36 年，HER2-/HR+的生存时间为 2.41 年，HER2+/HR-的生存时间为 2.82 年，三阴性患者的平均生存时间最短，为 1.74 年。总体人群的总成本为 46992731 欧元，HER2-/HR+为 190079787 欧元，HER2+/HR+为 151045260 欧元，HER2+/HR-为 80827171 欧元，三阴性亚组为 47540512 欧元。5 年内，每位患者的总费用平均为 160642 欧元，HER2-/HR+为 120664 欧元，HER2+/HR+为 290346 欧元，HER2+/HR-为 249152 欧元，三阴性患者为 94572 欧元。

结论

西班牙 mBC 的经济负担是巨大的，但因 HER2 和 HR 状态而异。由于该类别的患病率较高，HER2-/HR+患者的负担最高，但 HER2+/HR+患者的人均费用最高。